Tirzepatide

What Tirzepatide Does

Tirzepatide is a dual-agonist peptide that simultaneously activates two incretin receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It is the active ingredient in Mounjaro (diabetes) and Zepbound (weight management), both made by Eli Lilly. By hitting two receptor targets instead of semaglutide’s one, it produces more weight loss and better metabolic outcomes.

The mechanisms that matter:

• GLP-1 receptor agonism — the same pathway as semaglutide. Suppresses appetite centrally, delays gastric emptying, enhances glucose-dependent insulin secretion. The proven weight loss mechanism.
• GIP receptor agonism — the differentiator. GIP enhances pancreatic beta-cell function, improves insulin sensitivity in adipose tissue, promotes fat oxidation, and may independently reduce food intake. The dual activation creates a more comprehensive metabolic effect than GLP-1 alone.
• Insulin sensitization — tirzepatide improves insulin sensitivity more than semaglutide at equivalent weight loss, suggesting a direct metabolic benefit beyond weight reduction
• Beta-cell preservation — GIP signaling supports pancreatic beta-cell health and function, potentially slowing the progression of Type 2 diabetes

Why Two Receptors Matter

Semaglutide proved that targeting GLP-1 alone produces transformative weight loss. Tirzepatide showed that adding GIP agonism makes it better. The SURPASS-2 head-to-head trial showed tirzepatide 15 mg produced significantly more weight loss and better glycemic control than semaglutide 1 mg in Type 2 diabetes patients.

The GIP pathway contributes by:

1. Enhancing fat metabolism in adipose tissue — more efficient fat burning
2. Improving insulin sensitivity independent of weight loss — better glucose disposal
3. Supporting beta-cell function — more durable diabetes management
4. Potentially reducing nausea — some evidence suggests GIP activation mitigates GLP-1-related GI distress

Dosing Protocol

Standard Titration Schedule

Weeks	Dose	Purpose
Weeks 1–4	2.5 mg/week	Initiation — GI adaptation
Weeks 5–8	5 mg/week	First therapeutic dose
Weeks 9–12	7.5 mg/week	Escalation
Weeks 13–16	10 mg/week	Strong therapeutic range
Weeks 17–20	12.5 mg/week	Escalation
Week 21+	15 mg/week	Maximum dose

Total titration to max dose: 20 weeks. Each dose level runs for 4 weeks minimum before escalating.

Practical Notes

• Same day each week. Choose a consistent day. Minor timing variations (a few hours) don’t matter.
• Any time of day. No fasting requirement. With or without food.
• Injection site. Subcutaneous into abdomen, thigh, or upper arm. Rotate weekly.
• Missed dose: If within 4 days of the scheduled dose, take it as soon as possible. If 4+ days late, skip and resume on the next scheduled day.

Finding Your Maintenance Dose

The goal is the lowest effective dose — not necessarily 15 mg:

• 5 mg — meaningful appetite reduction, moderate weight loss, fewer GI side effects
• 10 mg — strong appetite suppression, significant weight loss. Many users find their sweet spot here.
• 15 mg — maximum weight loss. Most GI side effects. Not everyone tolerates it.

SURMOUNT-1 showed 15 mg produced 22.5% weight loss, but 10 mg produced 21.4% — the difference between 10 mg and 15 mg is modest. If 10 mg controls your appetite and you tolerate it well, staying there is reasonable.

Research-Grade Tirzepatide Reconstitution

For a 10 mg vial — add 2 mL bacteriostatic water:

Weekly Dose	Volume to Draw
2.5 mg	50 units on insulin syringe
5 mg	100 units (1 mL)
7.5 mg	150 units (1.5 mL)
10 mg	Full 2 mL

For higher doses (12.5–15 mg), you’ll need to draw from two vials or use a higher-concentration reconstitution. For a 30 mg vial — add 3 mL BAC water (10 mg/mL):

Weekly Dose	Volume to Draw
10 mg	100 units (1 mL)
12.5 mg	125 units (1.25 mL)
15 mg	150 units (1.5 mL)

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution.

Tirzepatide vs Semaglutide

The comparison everyone wants:

Feature	Tirzepatide (Zepbound)	Semaglutide (Wegovy)
Mechanism	Dual (GLP-1 + GIP)	Single (GLP-1)
Weight loss (max dose)	22.5% at 72 weeks	14.9% at 68 weeks
Insulin sensitivity	Greater improvement	Good improvement
Nausea rate	Similar (~25–30%)	Similar (~30–40%)
Cardiovascular data	SURPASS-CVOT ongoing	SELECT: 20% MACE reduction
Max dose	15 mg/week	2.4 mg/week
Titration time	20 weeks	16 weeks
Birth control interaction	Yes (reduces oral absorption)	No
Availability	Supply-constrained	Better availability
Cost (out of pocket)	~$1,000–1,200/month	~$1,000–1,300/month
Research-grade cost	~$100–200/month	~$80–150/month

Bottom line: Tirzepatide produces more weight loss. Semaglutide has proven cardiovascular protection. If maximum weight loss is the priority, tirzepatide is the stronger agent. If cardiovascular risk reduction matters (and you’re overweight with CV risk factors), semaglutide has the evidence.

What to Expect

Months 1–2 (2.5–5 mg)

• Gradual appetite reduction — more noticeable at 5 mg than 2.5 mg
• Learning to eat smaller portions naturally
• GI adaptation: mild nausea possible, usually resolves within 1–2 weeks at each dose
• Weight loss begins: 3–8 lbs in the first 8 weeks

Months 3–4 (7.5–10 mg)

• Strong appetite suppression — “food noise” significantly reduced
• Meals are noticeably smaller, food preferences may shift
• Steady weight loss: 1.5–2.5 lbs per week
• Metabolic markers improving (fasting glucose, triglycerides, HbA1c)
• Energy increasing as metabolic health improves

Months 5–6 (12.5–15 mg)

• Maximum therapeutic effect
• Weight loss continues but may begin to slow
• Body composition changes become clearly visible
• Blood pressure improvements common
• Insulin sensitivity significantly improved

Month 6+ (Maintenance)

• Weight loss typically plateaus at 12–18 months
• The drug maintains suppressed appetite and metabolic benefits
• Discontinuation leads to gradual weight regain

Side Effect Management

Common Side Effects

Similar profile to semaglutide but potentially milder at comparable weight loss levels (the GIP component may buffer GI distress):

Side Effect	Frequency	Management
Nausea	25–35%	Smaller meals, bland foods, avoid lying down post-meal
Diarrhea	15–25%	Hydrate, usually transient at each dose increase
Constipation	10–15%	Fiber, water, magnesium citrate
Decreased appetite	20–30%	This is the therapeutic effect — ensure adequate nutrition
Injection-site reactions	5–10%	Rotate sites, let alcohol dry before injecting
Fatigue	5–10%	Often from caloric deficit, not the drug. Eat enough protein

Oral Contraceptive Interaction

Critical for women: Tirzepatide delays gastric emptying, reducing oral contraceptive absorption by ~20%. The FDA recommends:

• Switch to non-oral contraception (IUD, implant, patch, ring) OR
• Use a barrier method (condoms) for 4 weeks after starting tirzepatide AND 4 weeks after each dose increase
• This is specific to tirzepatide — semaglutide does NOT have this interaction

Serious Side Effects (Rare)

• Pancreatitis — stop immediately if severe abdominal pain radiating to back. Same risk profile as semaglutide.
• Gallbladder disease — rapid weight loss increases gallstone risk. Monitor for right upper quadrant pain.
• Thyroid C-cell tumors — boxed warning based on rodent studies. Contraindicated with MTC/MEN 2 history.

Preserving Muscle Mass

Same principles as semaglutide — lean mass preservation is critical:

1. Resistance training 3–4x/week — the single most important intervention
2. Protein 1.2–1.6 g/kg/day — prioritize protein at every meal
3. Creatine 5g/day — supports muscle retention during deficit
4. Don’t over-restrict calories — let tirzepatide reduce appetite naturally, don’t stack aggressive restriction on top

What the Research Says

SURMOUNT-1 (Tirzepatide for weight loss, 72 weeks): 22.5% mean weight loss at 15 mg vs 3.1% placebo. Over one-third of participants lost 25%+ body weight. Published in NEJM, 2022.

SURMOUNT-4 (Discontinuation study): After 36 weeks of active treatment, participants randomized to placebo regained ~14% of body weight over 52 weeks, while those continuing tirzepatide lost an additional ~5.5%. Confirms the chronic treatment paradigm. JAMA, 2024.

SURPASS-2 (Head-to-head vs semaglutide in T2D): Tirzepatide 15 mg produced significantly more weight loss (-12.4 kg) than semaglutide 1 mg (-6.2 kg) and better HbA1c reduction. First direct comparison. NEJM, 2021.

Key practitioners:

• Peter Attia (The Drive) discusses tirzepatide vs semaglutide tradeoffs, emphasizing the lean mass preservation protocol
• Derek (MPMD) covers research-grade tirzepatide dosing and titration strategies

Safety

Do Not Use If

• Personal/family history of medullary thyroid carcinoma or MEN 2 syndrome
• History of pancreatitis
• Pregnant, planning pregnancy within 2 months, or breastfeeding
• Currently using another GLP-1 or GIP receptor agonist
• Type 1 diabetes
• Severe gastroparesis

Contraceptive Warning Reminder

Tirzepatide reduces oral contraceptive effectiveness. Switch to non-oral contraception or add barrier methods for 4 weeks after starting and after each dose change.

What Comes Next

• Compare alternatives — Semaglutide (single-agonist, cardiovascular data) or Retatrutide (triple-agonist, investigational)
• Read the full comparison — Weight Loss Peptides Compared
• Explore non-GLP-1 options — AOD-9604 for a peptide approach to fat loss
• Use the Reconstitution Calculator for research-grade dosing